Searching News Database: sumatriptan
HSMN NewsFeed - 11 Dec 2018
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
HSMN NewsFeed - 5 Jan 2018
Pernix Announces Reorganization of Sales Force to Focus on Zohydro(R) ER with BeadTek(TM) and Silenor(R)
Pernix Announces Reorganization of Sales Force to Focus on Zohydro(R) ER with BeadTek(TM) and Silenor(R)
HSMN NewsFeed - 31 Oct 2016
Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
HSMN NewsFeed - 22 Feb 2016
Lannett Receives FDA Approval For Sumatriptan Nasal Spray USP, 5mg And 20mg
Lannett Receives FDA Approval For Sumatriptan Nasal Spray USP, 5mg And 20mg
HSMN NewsFeed - 1 Jun 2015
POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
HSMN NewsFeed - 14 May 2014
POZEN Announces U.S. Rights for Treximet(R) to Be Acquired by Pernix Therapeutics
POZEN Announces U.S. Rights for Treximet(R) to Be Acquired by Pernix Therapeutics
HSMN NewsFeed - 17 Dec 2013
Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team
Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team
HSMN NewsFeed - 8 Nov 2012
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
HSMN NewsFeed - 11 Jan 2011
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
HSMN NewsFeed - 13 Jul 2010
Zogenix Secures $35 Million Debt Facility and Raises $15 Million Investment Capital
Zogenix Secures $35 Million Debt Facility and Raises $15 Million Investment Capital
HSMN NewsFeed - 14 Apr 2010
POZEN Enters into Settlement Agreement With Teva Regarding Paragraph IV Patent Litigation
POZEN Enters into Settlement Agreement With Teva Regarding Paragraph IV Patent Litigation
HSMN NewsFeed - 7 May 2008
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection
HSMN NewsFeed - 15 Apr 2008
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
HSMN NewsFeed - 21 Jan 2008
Ranbaxy Announces Settlement of Possible Imitrex(R) Litigation With GlaxoSmithKline
Ranbaxy Announces Settlement of Possible Imitrex(R) Litigation With GlaxoSmithKline
HSMN NewsFeed - 15 Jan 2008
POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM))
POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM))
HSMN NewsFeed - 31 Oct 2007
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
HSMN NewsFeed - 10 Oct 2007
NuPathe Inc. Names Jerry McLaughlin as Vice President of Commercial Operations
NuPathe Inc. Names Jerry McLaughlin as Vice President of Commercial Operations
HSMN NewsFeed - 5 Oct 2007
POZEN Plans to Submit Response to Approvable Letter For Trexima(TM) Within the Next Ten Days
POZEN Plans to Submit Response to Approvable Letter For Trexima(TM) Within the Next Ten Days
HSMN NewsFeed - 9 Aug 2007
Paladin And Glide Pharma Sign Exclusive Agreement for Novel Needle-Free Drug Delivery System
Paladin And Glide Pharma Sign Exclusive Agreement for Novel Needle-Free Drug Delivery System
HSMN NewsFeed - 8 Jun 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
HSMN NewsFeed - 7 Jun 2007
Zogenix Appoints David Nassif Executive Vice President and Chief Financial Officer
Zogenix Appoints David Nassif Executive Vice President and Chief Financial Officer
HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
HSMN NewsFeed - 23 Mar 2007
NovaDel's European Formulation of Ondansetron Targeted for U.S. Zensana(TM)
NovaDel's European Formulation of Ondansetron Targeted for U.S. Zensana(TM)
HSMN NewsFeed - 15 Nov 2006
Cobalt Announces Settlement of Imitrex(R) Litigation With GlaxoSmithKline
Cobalt Announces Settlement of Imitrex(R) Litigation With GlaxoSmithKline
HSMN NewsFeed - 13 Nov 2006
Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
HSMN NewsFeed - 16 Oct 2006
Zogenix Appoints J.D. Haldeman Vice President, Commercial Strategy & Corporate Communications
Zogenix Appoints J.D. Haldeman Vice President, Commercial Strategy & Corporate Communications
HSMN NewsFeed - 10 Oct 2006
Dr. Reddy's Announces Settlement of Imitrex(R) Litigation with GlaxoSmithKline
Dr. Reddy's Announces Settlement of Imitrex(R) Litigation with GlaxoSmithKline
HSMN NewsFeed - 28 Sep 2006
NovaDel Announces Positive Results from Pharmacokinetic Study of Improved Sumatriptan Oral Spray Formulation
NovaDel Announces Positive Results from Pharmacokinetic Study of Improved Sumatriptan Oral Spray Formulation
Additional items found! 43
Members Archive contains
43 additional stories matching:
sumatriptan
(Password required)
sumatriptan
(Password required)